Oncologie | Newsroom

newsroom

Oncologie, Inc. Announces Clinical Trial Collaboration With Merck to Evaluate Bavituximab in Combination With KEYTRUDA® (Pembrolizumab) in Advanced Gastric or Gastroesophageal Cancer

Press Release | August 12, 2019 | Source: Oncologie WALTHAM, Mass., Aug. 12, 2019 — Oncologie, Inc., a clinical-stage biopharmaceutical company developing innovative oncology treatments targeting the tumor microenvironment, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD outside the......
Oncologie Closes an $80M Series B Financing for Clinical-Stage Pipeline

Press Release | June 10, 2019 | Source: Oncologie BOSTON, June 10, 2019 — Oncologie, an innovative biopharmaceutical company using proprietary biomarkers to drive clinical development of next-generation oncology therapeutics, announced today that it has closed an $80M Series B financing. Existing investors, led by Nan Fung Life......

Oncologie Launches with 16.5M USD Seed Funding Led by Pivotal bioVenture Partners China

News Article | June 07, 2018 | Source: Oncologie, Inc. BOSTON and SHANGHAI, June 7, 2018 /PRNewswire/ — Oncologie, an innovative biopharmaceutical company, announced today that it is launching operations in both Boston and Shanghai with $16.5M seed financing led by Pivotal bioVenture Partners China. Oncologie is......
MOLOGEN Signs License Deal for China and Global Co-Development Agreement with Oncologie for Lead Compound lefitolimod

Press Release | February 13, 2018 | Source: Mologen BERLIN–(BUSINESS WIRE)–The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced today the signing of a license deal for the Chinese territory and a global co-development agreement between MOLOGEN and ONCOLOGIE Inc. for......
Avid Bioservices and Oncologie Enter Into Asset Assignment and Purchase Agreement for Avid’s PS-Targeting Program Including Bavituximab

Press Release | February 12, 2018 | Source: Avid Bioservices, Inc. TUSTIN, Calif. and BOSTON, Feb. 12, 2018 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Oncologie, Inc. today announced that the companies have entered into an Asset Assignment and Purchase Agreement for......